Related Experiment Video

Updated: May 26, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Targeted therapy for patients with chronic myeloid leukemia: clinical trial experience and challenges in inter-trial

Ramon Tiu1, Matt Kalaycio

  • 1Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

Leukemia & Lymphoma
|December 14, 2011
PubMed

Insights

Comparing tyrosine kinase inhibitor (TKI) efficacy in chronic myeloid leukemia (CML) trials is challenging due to varied patient histories. This review outlines methods to overcome these hurdles for more meaningful comparisons of CML treatments.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Trials

Background:

  • Chronic myeloid leukemia (CML) treatment advanced with imatinib mesylate, a tyrosine kinase inhibitor (TKI).
  • More potent TKIs like dasatinib and nilotinib were developed to enhance efficacy and tolerability in CML.
  • Comparing clinical efficacy of TKIs across different studies presents significant challenges for clinicians.

Purpose of the Study:

  • To identify challenges in comparing TKI efficacy across disparate CML clinical trials.
  • To propose solutions for improving the comparability of efficacy data from different CML studies.
  • To aid clinicians in making more informed treatment decisions for CML patients.

Main Methods:

  • Reviewing existing literature on CML treatment trials.
  • Analyzing confounding factors in cross-trial efficacy comparisons.
  • Identifying statistical and clinical methods to enhance data comparability.

Main Results:

  • Variable patient treatment histories complicate direct TKI efficacy comparisons.
  • Inconsistent definitions of imatinib resistance or intolerance pose challenges.
  • BCR-ABL mutational status at baseline is a critical factor for comparison.

Conclusions:

  • Careful consideration of confounding factors is essential for valid inter-trial comparisons.
  • Standardized methodologies can improve the comparability of CML trial data.
  • Enhanced inter-trial comparisons yield more clinically and statistically meaningful insights into TKI efficacy.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...